Dhuwit awis perusahaan Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals - logo grafis emiten EPRX

Eupraxia Pharmaceuticals (EPRX) minimizes operational risks by developing extended-release drug delivery systems for oncology and arthritis. Management is currently actively adapting these technologies to meet final clinical trial requirements. High physician confidence is based on the innovative drug delivery method. The current cash position demonstrates financial stability, while 0.13 determines the current value of this metric.

EPRX - Aset likuid perusahaan Eupraxia Pharmaceuticals ing rentang 06.04.2024 - 21.11.2026

Rincian metrik keuangan lan pasar eupraxiapharma.com (EPRX)

Pambiji fundamental perusahaan:Eupraxia Pharmaceuticals
Sampel barang Eupraxia Pharmaceuticals

For a fundamental valuation of Eupraxia Pharmaceuticals (EPRX), analyzing its financial stability amidst innovation development is critical. This metric measures the volume of liquid assets, determining the business's ability to cover operating expenses in the absence of revenue. By examining the history of cash reserves, an investor can assess the capital burn rate. This ensures the uninterrupted development of the long-acting drug ecosystem for arthritis therapy until the point of commercialization.

Pesaing langsung

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|BHST - Cadangan dhuwit perusahaan|eXoZymes - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan oramed.com ORMP|ENTX - Dana dhuwit perusahaan|Aset likuid perusahaan MindWalk Holdings HYFT|ABVC: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Cumberland Pharmaceuticals Inc.|Dana dhuwit perusahaan Quantum BioPharma Limited|FGEN: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan TELO|Rani Therapeutics Holdings, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Synergy CHC Corp. SNYR|Sisa dhuwit perusahaan RLYB|LEXX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Aptorum|Dhuwit awis perusahaan LYRA|Impact BioMedical Inc - Total volume dana dhuwit perusahaan|Volume dana dhuwit perusahaan TNFA|YCBD - Cadangan dhuwit perusahaan|PainReform Ltd. - Dhuwit awis perusahaan|CYTO (Auris Medical) - Total volume dana dhuwit perusahaan|LIPO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OPTN (OptiNose)|PIRS: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan